Abstract
Psoriasis is a multifaceted autoimmune disorder associated with irregularities in the T-cell function. Activation of T-cell produces enriches amounts of biomarkers which are highly responsible for keratinocyte hyperproliferation in psoriasis. Among the diverse drug therapies available for treatment and management of psoriasis, administration of omega (ω) - 3 fatty acids (i.e., EPA and DHA) and their metabolites as alone or combination with other antipsoriatic drugs in dose-dependent manner results to inhibit proinflammatory mediators. Despites their potential benefits, these bioactive are associated with limitations like lipid peroxidation and improper bioavailability after oral and topical administration. To overcome these hiccups, emergence of nanomedicines has gained wider attention owing to their improved stability, optimum bioavailability and better efficacy against psoriasis treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
